Authors

Latest:

Dr. Kapoor on LUGPA's Legislative Advocacy

Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association's (LUGPA's) chairman of health policy, discusses LUGPA's legislative advocacy efforts.

Deepika Narasimha, MD1, Anthony Jarkowski, III, PharmD2,and Nikhil I. Khushalani*, MD1,3

Deepu Madduri, MD

Latest:

CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to Know

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Deirdre J. Cohen, MD

Latest:

Dr. Deirdre Cohen on Emerging Agents in Gastric Cancer

Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

Delshad Ahmad, MD

Latest:

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Delvys Rodriguez-Abreu, MD

Latest:

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Demmie Aguilar

Latest:

Demmie Aguilar on Selecting a Clinical Trial Site

Demmie Aguilar, research coordinator, Clinical Research Division, Regional Cancer Care Associates, LLC, Central Jersey Division, discusses the qualities pharmaceutical companies look for when selecting a clinical trial site.

Deni Deasy Boekell

Latest:

The Evolving Use of White Bagging in Oncology

Channel dynamics are changing for physician-administered infusible drugs, with implications for practice economics, payer utilization management, site of care, and availability of data for manufacturers.

Denise A. Yardley, MD

Latest:

Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast Cancer

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Denise A. Yardley, MD, Sarah Cannon

Denise A. Yardley, MD, Sarah Cannon Research Institute

Denise Myshko

Senior Editor,

Latest:

No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

Denise R. Aberle, MD

Latest:

Dr. Aberle on Novel Approaches to Screening for Lung Cancer

Denise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.

Denise Soltow Hershey, PhD, RN, FNP-BC

Latest:

Improving Glycemic Control in Individuals With Cancer and Diabetes

It is estimated that 8%-18% of all cancer patients will have preexisting diabetes at the time they are diagnosed with cancer.

Denise Yardley, MD, Tennessee Oncology

Latest:

Dr. Yardley on Endocrine Therapy Plus CDK4/6 Inhibitors in Breast Cancer With Visceral Metastases

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Dennie V. Jones, Jr, M

Latest:

Hedgehog Signal Inhibition Hope or Hype?

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.

Dennis Bittner, PhD

Latest:

Liquid Biopsy Technology Grows More Varied and Potentially More Useful in NSCLC

The definition of liquid biopsy has expanded to include the collection of cell-free DNA (cfDNA), along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of patients with cancer.

Dennis C. Shrieve, MD, PhD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Dennis D. Hickstein, MD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Dennis Fitzgerald, MD

Latest:

Dr. Fitzgerald on Minimizing Use of Chemotherapy in Breast Cancer

Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.